{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:49:08Z","timestamp":1789685348214,"version":"4.0.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.ygyno.2006.06.028","type":"journal-article","created":{"date-parts":[[2006,8,7]],"date-time":"2006-08-07T14:36:17Z","timestamp":1154961377000},"page":"1083-1090","source":"Crossref","is-referenced-by-count":285,"title":["The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC\u2013IV epithelial ovarian cancer"],"prefix":"10.1016","volume":"103","author":[{"given":"Eric L.","family":"Eisenhauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem R.","family":"Abu-Rustum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Poynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Jarnagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald P.","family":"DeMatteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael I.","family":"D'Angelica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2006.06.028_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","article-title":"Cancer statistics, 2005","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J. Clin."},{"issue":"17","key":"10.1016\/j.ygyno.2006.06.028_bib2","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2006.06.028_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1200\/JCO.1986.4.4.515","article-title":"Prognostic factors in advanced ovarian carcinoma","volume":"4","author":"Redman","year":"1986","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2006.06.028_bib4","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.1991.9.7.1138","article-title":"Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience","volume":"9","author":"Omura","year":"1991","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2006.06.028_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/gyno.1998.4955","article-title":"Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study","volume":"69","author":"Eisenkop","year":"1998","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2006.06.028_bib6","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1054\/bjoc.2001.2030","article-title":"A prognostic model for ovarian cancer","volume":"85","author":"Clark","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2006.06.028_bib7","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1006\/gyno.2001.6328","article-title":"Identification of prognostic factors in advanced epithelial ovarian carcinoma","volume":"82","author":"Chi","year":"2001","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2006.06.028_bib8","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2006.06.028_bib9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/00006250-198606000-00007","article-title":"Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity","volume":"67","author":"Heintz","year":"1986","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2006.06.028_bib10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0090-8258(92)90107-T","article-title":"The impact of subspecialty training on the management of advanced ovarian cancer","volume":"47","author":"Eisenkop","year":"1992","journal-title":"Gynecol. Oncol."},{"issue":"3 Pt. 1","key":"10.1016\/j.ygyno.2006.06.028_bib11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/gyno.2000.5926","article-title":"A critique of surgical cytoreduction in advanced ovarian cancer","volume":"78","author":"Covens","year":"2000","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2006.06.028_bib12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1006\/gyno.1997.4839","article-title":"Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?","volume":"67","author":"Le","year":"1997","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2006.06.028_bib13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0090-8258(03)00278-6","article-title":"Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study","volume":"90","author":"Eisenkop","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2006.06.028_bib14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1006\/gyno.2000.5842","article-title":"Complete cytoreduction: is epithelial ovarian cancer confined to the pelvis biologically different from bulky abdominal disease?","volume":"78","author":"Naik","year":"2000","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2006.06.028_bib15","first-page":"927","article-title":"The management of diaphragmatic lesions in ovarian carcinoma","volume":"74","author":"Fiorica","year":"1989","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2006.06.028_bib16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/0090-8258(89)90074-7","article-title":"Resection of diaphragmatic peritoneum and muscle: role in cytoreductive surgery for ovarian cancer","volume":"35","author":"Montz","year":"1989","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2006.06.028_bib17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ygyno.2004.04.032","article-title":"Diaphragm resection for ovarian cancer: technique and short-term complications","volume":"94","author":"Cliby","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2006.06.028_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0090-8258(89)90068-1","article-title":"Splenectomy during primary maximal cytoreductive surgery for epithelial ovarian cancer","volume":"35","author":"Sonnendecker","year":"1989","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2006.06.028_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1006\/gyno.1998.5141","article-title":"Splenectomy in recurrent epithelial ovarian cancer","volume":"72","author":"Gemignani","year":"1999","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2006.06.028_bib20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1006\/gyno.1998.5145","article-title":"Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer","volume":"72","author":"Bristow","year":"1999","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2006.06.028_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ygyno.2005.08.036","article-title":"Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer","volume":"100","author":"Eisenkop","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2006.06.028_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","article-title":"Aggressive surgical effort and improved survival in advanced-stage ovarian cancer","volume":"107","author":"Aletti","year":"2006","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2006.06.028_bib23","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ygyno.2004.01.029","article-title":"Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach","volume":"94","author":"Chi","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2006.06.028_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.ygyno.2006.06.028_bib25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","article-title":"Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study","volume":"7","author":"Rustin","year":"1996","journal-title":"Ann. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2006.06.028_bib26","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","article-title":"Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels","volume":"19","author":"Rustin","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2006.06.028_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"issue":"3","key":"10.1016\/j.ygyno.2006.06.028_bib28","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.ygyno.2006.06.028_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc."},{"key":"10.1016\/j.ygyno.2006.06.028_bib30","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"Griffiths","year":"1975","journal-title":"Natl. Cancer Inst. Monogr."},{"issue":"5","key":"10.1016\/j.ygyno.2006.06.028_bib31","first-page":"349","article-title":"A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary","volume":"16","author":"Allen","year":"1995","journal-title":"Eur. J. Gynaecol. Oncol."},{"issue":"11\u201312","key":"10.1016\/j.ygyno.2006.06.028_bib32","first-page":"1727","article-title":"A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate","volume":"63","author":"Goldie","year":"1979","journal-title":"Cancer Treat. Rep."},{"issue":"2","key":"10.1016\/j.ygyno.2006.06.028_bib33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2006.06.028_bib34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1525-1438.2001.01027.x","article-title":"Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer","volume":"11","author":"Halperin","year":"2001","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2006.06.028_bib35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0090-8258(03)00068-4","article-title":"Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study","volume":"89","author":"Bloss","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2006.06.028_bib36","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0002-9378(92)91345-B","article-title":"The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer","volume":"166","author":"Rose","year":"1992","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2006.06.028_bib37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/gyno.2001.6344","article-title":"Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator","volume":"83","author":"Bristow","year":"2001","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2006.06.028_bib38","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1006\/gyno.2001.6375","article-title":"The effect of bowel resection on survival in advanced epithelial ovarian cancer","volume":"83","author":"Jaeger","year":"2001","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2006.06.028_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/gyno.1995.1027","article-title":"The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer","volume":"56","author":"Makar","year":"1995","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2006.06.028_bib40","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.1996.14.6.1895","article-title":"Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group","volume":"14","author":"Bookman","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2006.06.028_bib41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jnci\/dji102","article-title":"Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial","volume":"97","author":"Panici","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ygyno.2006.06.028_bib42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2006.06.028_bib43","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2006.06.028_bib44","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.1992.10.4.513","article-title":"Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population","volume":"10","author":"Markman","year":"1992","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2006.06.028_bib45","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2006.06.028_bib46","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2006.06.028_bib47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825806005166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825806005166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T10:15:47Z","timestamp":1736504147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825806005166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S0090825806005166"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2006.06.028","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}